Literature DB >> 12763684

The role of Toll-like receptor 2 in microbial disease and immunity.

Lee M Wetzler1.   

Abstract

Cells expressing Toll-like receptor (TLR), TLR2 in association with TLR1, TLR6 or some other unknown co-receptor can respond upon interaction with a large variety of microbial ligands. The variety of TLR2 ligands is the greatest among all the TLRs and this is due to the heterodimerization needed for TLR2 mediated responses. Like other TLRs, TLR2 signaling induces antigen presenting cell activation, pro-inflammatory cytokine production and increased expression of co-stimulatory ligand expression. These events are important for induction of innate immune responses and improved acquired immunity. There is strong suggestive evidence that alteration or lack of TLR2 function in vivo may correlate to decreased immune protection from pathogens that contain TLR2 ligands, but more work needs to be performed to strengthen this correlation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763684     DOI: 10.1016/s0264-410x(03)00201-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

Review 1.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

3.  Isolation and partial purification of macrophage- and dendritic cell-activating components from Mycoplasma arthritidis: association with organism virulence and involvement with Toll-like receptor 2.

Authors:  Barry C Cole; Hong-Hua Mu; Nathan D Pennock; Akira Hasebe; Fok V Chan; Leigh R Washburn; Morgan R Peltier
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 4.  Arterial Catheterization and Infection: Toll-like Receptors in Defense against Microorganisms and Therapeutic Implications.

Authors:  Zakary J Hambsch; Mitchell J Kerfeld; Daniel R Kirkpatrick; Dan M McEntire; Mark D Reisbig; Charles F Youngblood; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2015-08-14       Impact factor: 4.689

5.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 6.  Toll-like receptors and corneal innate immunity.

Authors:  Ashok Kumar; Fu-Shin X Yu
Journal:  Curr Mol Med       Date:  2006-05       Impact factor: 2.222

7.  Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS.

Authors:  Jannet Katz; Ping Zhang; Michael Martin; Stefanie N Vogel; Suzanne M Michalek
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

8.  Infection of mast cells with live streptococci causes a toll-like receptor 2- and cell-cell contact-dependent cytokine and chemokine response.

Authors:  Elin Rönnberg; Bengt Guss; Gunnar Pejler
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

9.  Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection.

Authors:  Angela Dolganiuc; Catherine Garcia; Karen Kodys; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

10.  TLR2 mediates recognition of live Staphylococcus epidermidis and clearance of bacteremia.

Authors:  Tobias Strunk; Melanie R Power Coombs; Andrew J Currie; Peter Richmond; Douglas T Golenbock; Liat Stoler-Barak; Leighanne C Gallington; Michael Otto; David Burgner; Ofer Levy
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.